Hillhouse Capital leads $230m Series B in US-based Gossamer Bio

Hillhouse Capital leads $230m Series B in US-based Gossamer Bio

Photo: Bloomberg

Beijing and Hong Kong-based Hillhouse Capital has led a $230-million Series B in Gossamer Bio Inc, a San Diego-based biotechnology company that develops therapeutic products, according to a statement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter